🍽️ todralazine hydrochloride non-drug

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastroesophageal Reflux Disease (GERD): Tenatoprazole, like other PPIs, is used to treat GERD by reducing the production of stomach acid. This can help alleviate symptoms such as heartburn, acid reflux, and esophagitis.

  2. Peptic Ulcers: PPIs are often used in the treatment of peptic ulcers, including gastric ulcers and duodenal ulcers. By reducing stomach acid production, tenatoprazole can help promote healing and prevent ulcer recurrence.

  3. Zollinger-Ellison Syndrome: This rare condition involves excessive gastric acid production due to gastrin-secreting tumors in the pancreas or duodenum. PPIs like tenatoprazole can help manage symptoms and reduce acid production in individuals with this syndrome.

  4. Helicobacter pylori Infection: Tenatoprazole is sometimes used as part of a combination therapy to eradicate Helicobacter pylori bacteria in the stomach, which can help heal ulcers and prevent their recurrence.

  5. Reflux Esophagitis: Inflammation of the esophagus due to chronic acid reflux can be treated with PPIs like tenatoprazole, which help reduce acid exposure to the esophageal lining.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of todralazine hydrochloride non-drug On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by todralazine hydrochloride non-drug

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Akkermansia genus Decreases 📓 Source Study
Escherichia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Akkermansia glycaniphila species Decreases 👶 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of todralazine hydrochloride non-drug on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 0.1 0.3 -2
Allergic Rhinitis (Hay Fever) 0.9 0.9
Allergies 0.4 0.2 1
Allergy to milk products 0.1 0 0
Alzheimer's disease 0.2 0.1 1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.1 0.2 -1
Ankylosing spondylitis 0.1 0.9 -8
Anorexia Nervosa 0.1 -0.1
Antiphospholipid syndrome (APS) 0.1 0 0
Asthma 0.7 0.1 6
Atherosclerosis 0.1 0 0
Atrial fibrillation 0.1 0.1 0
Autism 1.7 0.2 7.5
benign prostatic hyperplasia 0 0
Biofilm 0.9 0.9
Bipolar Disorder 0.1 0.4 -3
Cancer (General) 0.7 -0.7
Carcinoma 0.5 0.1 4
Celiac Disease 0.1 0.1 0
Cerebral Palsy 0 0.1 0
Chronic Fatigue Syndrome 2.6 0.1 25
Chronic Kidney Disease 1.2 1.2
Chronic Urticaria (Hives) 0.1 0.1 0
Coagulation / Micro clot triggering bacteria 0.1 0.1 0
Colorectal Cancer 0.2 0.2
Constipation 0 0
Coronary artery disease 0.9 0.9
COVID-19 1.2 0.6 1
Crohn's Disease 1.4 0.1 13
cystic fibrosis 0.1 0.1
deep vein thrombosis 0.1 0.1 0
Depression 2.1 0.8 1.63
Eczema 0.9 0.9
Endometriosis 0.1 0.1 0
Epilepsy 0.1 0.1 0
Functional constipation / chronic idiopathic constipation 0.2 0.2
gallstone disease (gsd) 0.1 0.1
Generalized anxiety disorder 0.9 0.9
Hashimoto's thyroiditis 0 0 0
Hidradenitis Suppurativa 0 0
High Histamine/low DAO 0.1 0.1 0
hypercholesterolemia (High Cholesterol) 0.1 -0.1
hyperglycemia 0 0.1 0
Hyperlipidemia (High Blood Fats) 0 0
hypersomnia 0 0
hypertension (High Blood Pressure 0.1 0.1 0
Hypothyroidism 0.3 -0.3
Hypoxia 0 0
IgA nephropathy (IgAN) 0.8 -0.8
Inflammatory Bowel Disease 1.3 0.3 3.33
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.2 0.1 1
Liver Cirrhosis 0.2 0.1 1
Long COVID 1.2 0.2 5
Lung Cancer 0 0.1 0
Mast Cell Issues / mastitis 0 0.1 0
ME/CFS without IBS 2 2
Metabolic Syndrome 1.4 0.2 6
Mood Disorders 2.2 1.2 0.83
multiple chemical sensitivity [MCS] 0 0
Multiple Sclerosis 1.2 0.1 11
Multiple system atrophy (MSA) 0.1 0.1 0
neuropathic pain 0 0
Neuropathy (all types) 0 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0.1 0
Obesity 1 0.8 0.25
obsessive-compulsive disorder 0.2 0.9 -3.5
Osteoarthritis 0.9 0.1 8
Osteoporosis 0.4 0.1 3
Parkinson's Disease 0.5 0.1 4
Polycystic ovary syndrome 0.1 0.2 -1
Psoriasis 0.2 0.1 1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.3 1.3
Rosacea 0.1 0.1
Schizophrenia 0.5 0.1 4
scoliosis 0.1 -0.1
Sjögren syndrome 0 0
Sleep Apnea 0.1 0.3 -2
Slow gastric motility / Gastroparesis 0.1 0.1
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 0.1 0.7 -6
Systemic Lupus Erythematosus 1.2 0.1 11
Tic Disorder 0.1 0.1
Tourette syndrome 0 0
Type 1 Diabetes 0.1 0.1
Type 2 Diabetes 1.4 0.2 6
Ulcerative colitis 0.4 0.1 3
Unhealthy Ageing 1.2 0 0

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]